Reveal LINQ

The Reveal LINQ Insertable Cardiac Monitor (Model LNQ11) is designed for long-term subcutaneous ECG monitoring to automatically detect and record various cardiac arrhythmias in symptomatic patients or those at high risk, utilizing patient-activated and auto-activated event recording. This specific device iteration incorporates firmware modifications focused on enhancing arrhythmia detection accuracy by implementing new rules to reduce false positives for atrial and ventricular arrhythmias, validated through extensive bench testing.

The Reveal LINQ Insertable Cardiac Monitor (Model LNQ11) is a small, leadless device implanted subcutaneously in the chest for long-term cardiac monitoring. It continuously records subcutaneous ECG using two electrodes and is indicated for patients with clinical syndromes or situations at increased risk of cardiac arrhythmias, or those experiencing transient symptoms like dizziness, palpitation, syncope, and chest pain suggestive of an arrhythmia. The system employs both automatic activation and patient-activated recording to capture various arrhythmias, including atrial tachyarrhythmia/atrial fibrillation (AT/AF), bradyarrhythmia, pause, and fast ventricular tachyarrhythmia, storing ECG and marker channel data for these events. The device features a hermetically enclosed battery with a 3-year usable capacity, an electronics module with analog, digital, and memory ICs, and a molded header with a Titanium Nitride coated sensing electrode and RF antenna; body contacting materials include Titanium, Parylene, Urethane, and Titanium Nitride. This particular iteration introduces modified firmware designed to enhance atrial and ventricular arrhythmia detection by adding three specific rules: an Adaptive P-sense rule, a Dual Sense Brady rejection rule, and a Dual Sense Asystole rejection rule, all aimed at reducing false positive detections. The update also incorporates minor diagnostic and telemetry updates, LINQ RRT integration, and bug fixes, with its performance and safety validated through comprehensive firmware regression, design verification, system verification, and system design validation testing, including adherence to the ANSI/AAMI EC57:1998 standard for cardiac rhythm algorithm performance.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What is the quantified impact of the new 'Adaptive P-sense rule,' 'Dual Sense Brady rejection rule,' and 'Dual Sense Asystole rejection rule' on the reduction of false positive rates for specific arrhythmias, and what was the baseline false positive rate?; What are the specific 'minor diagnostic updates' and 'minor telemetry updates' implemented in this firmware, and how do they tangibly improve clinical utility or data management for the end-user?; Although not tested for pediatric use, what are the primary physiological or anatomical contraindications or challenges anticipated if this device were considered for pediatric patients?; How does the 'LINQ RRT update integration' specifically enhance the device's remote monitoring capabilities or data transmission protocols?; Can you provide examples of the 'minor bug fixes' implemented and detail their potential impact on device performance or data integrity prior to these corrections?